( " F C P A " ) , 15 U . S . C . 7 8 - - PDF document

SLIDE 1

t

In

• r

d e r t

• a

d d r e s s

a n y

d e f i c i e n c i e s i n

i t s

i n t e r n a l c

• n

t r

• l

s , policies,

a n d p r

• c

e d u r e s regarding compliance with t h e Foreign Corrupt P r a c t i c e s

A c t

(

" F C P A

" ) ,

15 U . S . C . § § 7 8 d d

• 1

, e t s e q . ,

a n d

• t

h e r a p p l i c a b l e a n t i

• c
• r

r u p t i

• n

laws, P f i z e r I n c .

and

i t s subsidiaries

a n d

• perating

companies

(collectively, " P f i z e r

")

a g r e e to c

• n

t i n u e to conduct appropriate reviews

• f

i t s

e x i s t i n g internal controls, p

• l

i c i e s ,

a n d

p r

• c

e d u r e s .

Where

necessary a n d a p p r

• p

r i a t e , P f i z e r agrees to

a d

• p

t

n e w

• r

t

• m
• d

i f y

e x i s t i n g i n t e r n a l c

• n

t r

• l

s , p

• l

i c i e s ,

a n d p r

• c

e d u r e s i n

• rder

to e n s u r e t h a t

i t

m a i n t a i n s :

( a ) a system

• f

i n t e r n a l accotulting c

• n

t r

• l

s designed t

• e

n s u r e

t h a t P f i z e r

m a k e s a n d k e e p s

fair

and

accurate

b

• k

s ,

r e c

• r

d s ,

a n d

a c c

• u

n t s ;

a n d (b)

rigorous

a n t i

• corruption

c

• m

p l i a n c e c

• d

e , standards, a n d p r

• c

e d u r e s

• d

e s i g n e d to d e t e c t a n d d e t e r

v i

• l

a t i

• n

s

• f

t h e

FCPA

a n d

• ther

a p p l i c a b l e

a n t i

• c
• r

r u p t i

• n

l a w s .

A t

a

m i n i m u m ,

t h i s

s h

• u

l d include, b u t not

b e

L i m i t e d t

• ,

the f

• l

l

• w

i n g elements:

A

c l e a r l y a r t i c u l a t e d c

• r

p

• r

a t e policy a g a i n s t v i

• l

a t i

• n

s

• f

t h e

F C P A ,

i n c l u d i n g

i t s anti

• bribery,

books a n d

r e c

• r

d s ,

a n d

internal c

• n

t r

• l

s provisions,

a n d

• t

h e r a p p l i c a b l e counterparts ( c

• l

l e c t i v e l y , the "anti-corruption

l a w s

" ) ; 2 .

Promulgation

• f

c

• m

p l i a n c e s t a n d a r d s a n d p r

• c

e d u r e s d e s i g n e d to reduce t h e p r

• s

p e c t

• f

v i

• l

a t i

• n

s

• f

the anti-corruption l a w s a n d P f i z e r ' s c

• m

p l i a n c e

• code. These

s t a n d a r d s

a n d

p r

• c

e d u r e s

s h a l l

a p p l y

to

a l l directors,

• fficers,

a n d employees

a n d ,

w h e r e

necessary

and

a p p r

• p

r i a t e ,

• u

t s i d e p a r t i e s w h i l e a c t i n g

• n

b e h a l f

• f

P f i z e r i n

a

f

• r

e i g n j u r i s d i c t i

• n

, i n c l u d i n g

b u t not

l i m i t e d t

• ,

a g e n t s , c

• n

s u l t a n t s , r e p r e s e n t a t i v e s , d i s t r i b u t

• r

s ,

teaming

partners,

a n d

joint v e n t u r e p a r t n e r s ( c

• l

l e c t i v e l y ,

"agents a n d business p a r t n e r s " ) ;

: ~ ~

SLIDE 2

T h e

a s s i g n i i ~ e n t

• f

r e s p

• n

s i b i l i t y t

• ne
• r

m

• r

e

s e n i

• r

c

• r

p

• r

a t e e x e c u t i v e s

• f

P f i z e r f

• r

t h e implementation

a n d

• v

e r s i g h t

• f

c

• m

p l i a n c e with

policies, standards,

a n d

p r

• c

e d u r e s r e g a r d i n g t h e

a n t i

• c
• r

r u p t i

• n
• laws. Such

c

• r

p

• r

a t e

• f

f i c i a l s ) s h a l l

h a v e

the a u t h

• r

i t y to r e p

• r

t m a t t e r s directly t

• P

f i z e r ' s

Board

• f

D i r e c t

• r

s

• r

a n y

appropriate c

• m

m i t t e e

• f

the

B

• a

r d

• f

Directors; 4.

Mechanisms

d e s i g n e d to ensure

that

the policies, standards, and p r

• c

e d u r e s

• f

P f i z e r r e g a r d i n g t h e a n t i

• c
• r

r u p t i

• n

laws

are e f f e c t i v e l y

communicated

to

a l l

directors,

• f

f i c e r s ,

e m p l

• y

e e s , a n d , where

a p p r

• p

r i a t e , agents

a n d business

p a r t n e r s .

T h e s e m e c h a n i s m s

s h a l l include:

(a)

p e r i

• d

i c t r a i n i n g f

• r

a l l

d i r e c t

• r

s ,

• f

f i c e r s ,

and e m p l

• y

e e s , and, w h e r e n e c e s s a r y a n d

appropriate, agents

and

b u s i n e s s partners;

a n d ( b ) a c c

• m

p a n y i n g

c e r t i f i c a t i

• n

s

b y

a l l

such

d i r e c t

• r

s ,

• fficers,

a n d employees, a n d , where

n e c e s s a r y

a n d

a p p r

• p

r i a t e , a g e n t s ,

a n d

b u s i n e s s partners, c e r t i f y i n g c

• m

p l i a n c e w i t h the

t r a i n i n g r e q u i r e m e n t s ;

A n

e f f e c t i v e

s y s t e m f

• r

r e p

• r

t i n g suspected crimuial

conduct a n d /

• r

v i

• l

a t i

• n

s

• f

the c

• m

p l i a n c e

policies, s t a n d a r d s ,

a n d procedures regarding

t h e

a n t i

• c
• n
• u

p t i

• n

l a w s

f

• r

directors,

• f

f i c e r s ,

e m p l

• y

e e s , a n d , where necessary and a p p r

• p

r i a t e , agents

and business

partners; 6 . Appropriate disciplinary procedures to a d d r e s s , .

a m

• n

g

• ther

t h i n g s , v i

• l

a t i

• n

s

• f

t h e anti-corruption

l a w s a n d

P f i z e r ' s

c

• m

p l i a n c e c

• d

e

b y

Pfizer's d i r e c t

• r

s ,

• f

f i c e r s ,

a n d e m p l

• y

e e s ;

7 . Appropriate

d u e

diligence r e q u i r e m e n t s pertaining to t h e retention

a n d

• v

e r s i g h t

• f

a g e n t s

a n d

b u s i n e s s p a r t n e r s ; Standard p r

• v

i s i

• n

s in a g r e e m e n t s , c

• n

t r a c t s ,

a n d r e n e w a l s

thereof w i t h

a l l

a g e n t s

a n d

b u s i n e s s p a r t n e r s t h a t are r e a s

• n

a b l y calculated to p r e v e n t violations

• f

the anti-

c

• m

t p t i

• n

l a w s , w h i c h

m a y ,

depending

upon

t h e c i r c u m s t a n c e s , include:

( a )

a n t i-corruption

C . 1-2

SLIDE 3

representations

and

undertakings

relating to

compliance w i t h the

anti-corruption laws;

( U )

rights

to c

• n

d u c t

audits

• f

the books and records

• f

t h e agent

• r

b u s i n e s s partner

t

• ensiue

complialice

w i t h the foregoing; and (c)

rights t

• t

e r m i n a t e an agent

• r

business partner a s a

result

• f

ally

breach

• f

a n t i

• con~uption

laws, and regulations

• r

representations

a n d

undertakings related t

• such

matters;

a n d

9. P e r i

• d

i c

t e s t i n g

• f

the compliance code, standards, and procedures designed to evaluate

their effectiveness in detecting

and reducing

violations

• f

a n t i

• corruption

laws and

Pfizer's

compliance code.

C.1-3

SLIDE 4

ATT'r~CI-

~l~~I~1~'

C . 2 In

addition t

• a

n d

building

u p

• n

the

commitments enumerated

i n Attachment C . 1 , P f i z e r Inc.

a n d

its

s u b s i d i a r i e s

acid operating

c

• m

p a n i e s

( c

• l

l e c t i v e l y , "Pfizer

" )

agree t h a t t h e y have t a k e n

• r

will u n d e r t a k e the f

• l

l

• w

i n g , at a

minimum,

f

• r

the duration

• f

the D e f e r r e d Prosecution

A g r e e m e n t between

the United

S t a t e s

Department

• f

Justice,

C r i m i n a l Division, F r a u d Section (the "Department

" )

a n d

Pfizer

H.C.P. C

• r

p

• r

a t i

• n

d a t e d

~ '

G e n e r a l

Pfizer

will: a.

Maintain the a p p

• i

n t m e n t

• f

a

senior corporate e x e c u t i v e w i t h significant e x p e r i e n c e w i t h compliance w i t h the

F C P A ,

i n c l u d i n g

its

a n t i

• bribery,

b

• k

s and

r e c

• r

d s ,

and

internal controls provisions,

as w e l l as

• ther

applicable

anti-

c

• r

r u p t i

• n

l a w s and

regulations (hereinafter "anti- c

• r

r u p t i

• n

laws a n d

regulations") to serve a s

C h i e f C

• m

p l i a n c e and Risk

Officer.

T h e

C h i e f C

• m

p l i a n c e and R i s k

Officer will

h a v e

r e p

• r

t i n g

• bligations

directly t

• t

h e Chief E x e c u t i v e Officer and periodic r e p

• r

t i n g

• b

l i g a t i

• n

s t

• the

Audit Committee

• f

the

B

• a

r d

• f

D i r e c t

• r

s .

b . M a i n t a i n the a p p

• i

n t m e n t

• f

heads

• f

compliance with

r e s p

• n

s i b i l i t y f

• r

each

• f

i t s

business units

(

"BU

Compliance L e a d s

" ) w h

• h

a v e

reporting

• bligations

t h r

• u

g h the C h i e f Compliance a n d Risk Officer

• r

General Counsel.

c. Establish

and

m a i n t a i n an "Executive

Compliance C

• m

m i t t e e "

t

• v

e r s e e P f i z e r ' s corporate c

• m

p l i a n c e p r

• g

r a m with

r e s p e c t t

• both

the

laws and

regulations applicable to Pfizer's business

and

t

• P

f i z e r ' s

C

• d

e

• f

Conduct and

r e l a t e d

C 2

• 1

SLIDE 5

• policies. The

E x e c u t i v e Compliance

Committee

is

chaired

by

the

Chief E x e c u t i v e

O f f i c e r ,

and

includes appropriate s e n i

• r

leaders,

s u c h as the Chief

Financial Officer, the General

C

• u

n s e l and

senior leaders

from

compliance, finance,

audit,

human

r e s

• u

r c e s and P f i z e r ' s business units. 2. Pfizer has

a n d

will maintain

gifts, hospitality,

and

travel p

• l

i c i e s

and procedures in

each jurisdiction that are appropriately designed to prevent violations

• f

the anti-corruption

l a w s and

regulations. ,Specifically, Pfizer

h a s implemented and

will maintain the

f

• l

l

• w

i n g e n h a n c e d

anti-con-uption policies

and p r

• c

e d u r e s :

a.

A

Global Anti-Bribery a n d Anti-Corruption C

• r

p

• r

a t e Policy and

a n

International

Anti-Bribery and Anti-Corruption Procedure (the

" F C P A

Procedure "), which

are

supported

by

implementing

standard

• perating

p r

• c

e d u r e s

by

market, region

• r

f u n c t i

• n

as appropriate;

and which provide

detailed procedures for

employees

t

• follow

when

interacting

with f

• r

e i g n

government

• fficials

and conducting

F C P A

due

diligence

• n

consultants, technical advisors, researchers

and

grant

recipients

a n d , w h e r e

appropriate, in

c

• m

m e r c i a l

transactions with "agents

and

business p a r t n e r s " (as defined in Attachment C . 1 ) .

The

FCPA

Procedure

establishes

procedures and

specific

l i m i

±s governing

the provision

by

P f i z e r ' s

employees

• f

gifts, hospitality, international travel

and

site visits,

meeting s u p p

• r

t , e d u c a t i

• n

a l g r a n t s , charitable d

• n

a t i

• n

s ,

and

c

• n

s u l t i n g f e e s , speaker fees, honoraria,

a n d

the like to foreign

government

• fficials. All
• f

these procedures a r e in the local language

when

appropriate. b .

A

Global P

• l

i c y

• n

Interactions with

Healthcare Professionals

w h i c h

is

supported

by

implementing

standard

• perating

procedures

by

m a r k e t , region

• r

function, as appropriate, establishing ethical standards

and

p r

• c

e d u r e s f

• r

Pfizer

employees

t

• C.2
• 2

SLIDE 6

follow

when

interacting with physicians, nurses,

and

• t

h e r such

h u m a n

healthcare professionals, including standards related to

product s a m p l e s , support

f

• r

c

• n

f e r e n c e s ,

a n d

practice-related i t e m s . c.

At

a

m i n i m u m ,

these policies

and procedures

shall contain the following restrictions regarding foreign

g

• v

e r n m e n t

• fficials,

including but not limited to p u b l i c h e a l t h care providers, a d m i n i s t r a t

• r

s ,

and

regulators: Gifts

must be modest

in value, appropriate

under

the c i r c u m s t a n c e s , and given in accordance w i t h

anti-comtption

laws and

r e g u l a t i

• n

s , including t h

• s

e

• f

the

g

• v

e r n m e n t

• fficial's home

c

• u

n t r y ;

i i .

Hospitality s h a l l

be

limited t

• reasonably

priced m e a l s , accommodations,

a n d

incidental

expenses

that are p a r t

• f

product e d u c a t i

• n

and gaining programs,

professional training,

and conferences

• r

business meetings;

iii.

Travel

shall

be

limited to product education

and

training

p r

• g

r a m s , professional

training

and

education,

and conferences

• r

business meetings;

and

iv. Gifts, hospitality,

a n d

travel shall

not include expenses for anyone

• t

h e r

t h a n the

relevant

• fficials,

unless d i f f e r e n t standards are required

b y

l

• c

a l

law

• r

regulation. C'omplaint~,

I2epoa~ts,

and

C'o~apliance

Issues Pfizer h a s c

• m

m i t t e d and

will continue the

commitment

• f

significantly

enhanced r e s

• u

r c e s f

• r

the international functions

• f

the

Compliance Division

that

h a v e

reporting

• bligations

t h r

• u

g h the Chief C

• m

p l i a n c e and Risk

O f f i c e r

• r

General Counsel, i n c l u d i n g the following:

C.2-3

SLIDE 7

a .

An

i n t e r n a t i

• n

a l i n v e s t i g a t i

• n

s

g r

• u

p c h a r g e d w i t h responding t

• and

investigating anti-corruption

compliance

i s s u e s r e p

• r

t e d

• n

a global

basis

a c i d

e n s u r i n g t h a t appropriate remedial measures a r e u n d e r t a k e n

after

the completion

• f

an

investigation;

b .

An

anti-corruption

program

• ffice

providing c e n t r a l i z e d assistance and guidance r e g a r d i n g the i m p l e m e n t a t i

• n

, u p d a t i n g a n d revising

• f

t h e

FCPA

P r

• c

e d u r e , the establishment

• f

systems to e n h a n c e compliance w i t h t h e

F C P A

P r

• c

e d u r e , a n d the administration

• f

corporate-level training

a n d annual

a n t i

• c
• r

r u p t i

• n

c e r t i f i c a t i

• n

s ;

a n d

c .

A

mergers and

a c q u i s i t i

• n

s

compliance function designed to s u p p

• r

t early

identification

• f

c

• m

p l i a n c e

risks a s s

• c

i a t e d w i t h

c

• m

p l e x

business transactions

and

to ensure the integration

• f

P f i z e r ' s

c

• m

p l i a n c e p r

• c

e d u r e s

into

n e w l y

a c q u i r e d

entities.

4 . Pfizer

shall maintain

its mechanisms

for

m a k i n g a n d h a n d l i n g

reports

a n d

complaints related to p

• t

e n t i a l v i

• l

a t i

• n

s

• f

a n t i

• c
• r

r u p t i

• n

l a w s and

r e g u l a t i

• n

s , including,

when

a p p r

• p

r i a t e ,

referral

for r e v i e w

and response b y

internal audit, finance, l e g a l ,

c

• m

p l i a n c e

and

• ther

p e r s

• n

n e l a s appropriate,

and

will

ensure

t h a t

reasonable a c c e s s

is

provided to

an anonymous,

toll

• f

r e e hotline a s

w e l l a s to

an anonymous

electronic

c

• m

p l a i n t form,

where anonymous

r e p

• r

t i n g

i s

legally p e r m i s s i b l e .

5. Pfizer, t h r

• u

g h

its

E x e c u t i v e C

• m

p l i a n c e C

• m

m i t t e e ,

~ ~ i l l

ensure t h a t the Compliance

and Legal

Divisions r e v i e w

and r e s p

• n

d

t

• FCPA

and

c

• r

r u p t i

• n

issues

promptly a n d

c

• n

s i s t e n t l y . C . 2

• 4

SLIDE 8

d i s k

14ssess~a~erzt~

a n d ~r

• a

c t i v e

Reviews

6 . Pfizer has conducted a n d

will c

• n

t i n u e to conduct a r i s k

• based

program

• f

amlual p r

• a

c t i v e

anti-corruption

reviews

• f

h i g h

• risk

m a r k e t s .

These

F C P A

proactive reviews a r e designed to identify a n t i

• corruption

c

• n

7 p l i a n c e issues,

examine compliance p r

• c

e d u r e s and

controls a s

i m p l e m e n t e d

in the f i e l d

and

identify best p r a c t i c e s t

• be

implemented

in additional

• markets. On

the basis

• f

those assessments, as needed, P f i z e r will

modify compliance

i m p l e m e n t a t i

• n

to

minimize

risks

• b

s e r v e d through t h e

FCPA

p r

• a

c t i v e r e v i e w process. 7. Specifically, Pfizer will i d e n t i f y m a r k e t s

which

are at h i g h risk for con-uption b e c a u s e

• f

t h e i r

b u s i n e s s and location, a n d will

select at l e a s t five

• f

those m a r k e t s to receive

FCPA

p r

• a

c t i v e reviews during t h a t year.

H i g h

risk

m a r k e t s

s h a l l

be

i d e n t i f i e d

based

• n

P f i z e r ' s risk a s s e s s m e n t p r

• c

e s s in consultation w i t h t h e

Chief Compliance and Risk

Officer, taking into account multiple risk factors including,

but n

• t

l i m i t e d to: a h i g h

d e g r e e

• f

interaction with f

• r

e i g n

government

• fficials;

the e x i s t e n c e

• f

internal reports

• f

p

• t

e n t i a l c

• r

r u p t i

• n

risk;

a

h i g h corruption

risk

based

• n

certain corruption i n d e x e s ;

a n d

financial a u d i t

• results. Each

F C P A

proactive

r e v i e w

shall i n c l u d e , at

a m i n i m u m :

a.

On-site

v i s i t s

b y

a n

FCPA

review

team c

• m

p r i s e d

• f

qualified personnel

f r

• m

t h e

Compliance and, w h e n

a p p r

• p

r i a t e ,

L e g a l Divisions

who

h a v e

r e c e i v e d

F C P A

and

anti-corruption t r a i n i n g ; b .

W h e r e

a p p r

• p

r i a t e , participation in the

• n
• site

v i s i t s

by

qualified a u d i t

• r

s ; c.

R e v i e w

• f

a

r e p r e s e n t a t i v e

sample, appropriately a d j u s t e d f

• r

the risks

• f

the m a r k e t ,

• f

c

• n

t r a c t s w i t h

and p a y m e n t s

to individual foreign

g

• v

e r n m e n t

• fficials
• r

h e a l t h care providers, a s w e l l a s

• ther

high

• r

i s k t r a n s a c t i

• n

s i n the m a r k e t ;

C . 2

• 5

SLIDE 9

d. C r e a t i

• n
• f

a c t i

• n

plans r e s u l t i n g

from

issues i d e n t i f i e d during

F C P A

p r

• a

c t i v e reviews; these action plans will

be shared w i t h

appropriate senior

m a n a g e m e n t ,

including

when

appropriate the

Chief Compliance a n d Risk

Officer,

and

w i l l contain

mandatory remedial

steps designed to

e n h a n c e

anti-corruption

compliance,

r e p a i r process

weaknesses, a n d d e t e r

violations;

a n d

e.

Where

appropriate, feasible,

a n d

permissible

u n d e r

local

law, review

• f

the b

• k

s and records

• f

a sample

• f

distributors which,

i n the

view

• f

the

FCPA

proactive

review team,

m a y

present corruption

risk.

8. Pfizer has implemented a n d

will continue to

implement an

FCPA

trend analysis that r e q u i r e s various

• perational

f u n c t i

• n

s t

• track

a n d review

certain categories

• f

i n t e r a c t i

• n

s w i t h foreign

government

• fficials and

due

diligence

• n

a g e n t s

and

business partners. ~4cquisitions Pfizer

has ensured and

will continue to

ensure

that,

when

practicable

and

appropriate

• n

the basis

• f

a

FCPA

r i s k

assessment,

new

b u s i n e s s

entities

a r e

• nly

a c q u i r e d

after

thorough

risk-based

FCPA

and

a n t i- corruption

d u e

diligence

was

conducted

by

a

suitable

combination

• f

legal, accounting,

and compliance

personnel.

W h e n

s u c h

anti-corruption

d u e

diligence

is

appropriate but not practicable prior to acquisition

• f

a

new

business for reasons

beyond

Pfizer's control,

• r

d u e

to

a n y

applicable

l a w ,

rule,

• r

regulation, Pfizer

has conducted and

will

c

• n

d u c t

anti-corruption

due

diligence subsequent to the acquisition

and

report to the

Department any corrupt p a y m e n t s

• r

falsified

books a n d records as

required

by

Attachment C.3.

C.2

• 6

SLIDE 10

I0. P f i z e r

w i l l

e n s u r e

t h a t Pfizer's p

• l

i c i e s , s t a n d a r d s

and procedures

regarding

a n t i

• con~uption

laws a n d

r e g u l a t i

• n

s

a p p l y as q u i c k l y as

is practicable,

b u t i n

a n y

e v e n t

no more than

• ne

y e a r post

• closing,

t

• n

e w l y

• a

c q u i r e d businesses, a n d

will

p r

• m

p t l y :

a . T r a i n d i r e c t

• r

s ,

• f

f i c e r s ,

a n d senior m a n a g e r s , and those employees working

i n positions i n v

• l

v i n g

activities covered

by

P f i z e r ' s p

• l

i c i e s r e g a r d i n g a n t i

• c
• r

r u p t i

• n

and c

• m

p l i a n c e w i t h t h e

FCPA,

a n d , where necessary a n d

appropriate, a g e n t s

and business

partners;

and

b . I n c l u d e

a l l

newly-acquired businesses

in P f i z e r ' s r e g u l a r anti-corruption a u d i t i n g schedule. I~elatioreshzps with 7'Izird Pa~Pies 1 1 .

W h e n

a p p r

• p

r i a t e

• n

the basis

• f

a

FCPA

risk

a s s e s s m e n t , Pfizer

w i l l

conduct

risk-based

due

diligence

• f

s a l e s i n t e r m e d i a r i e s , i n c l u d i n g agents, c

• n

s u l t a n t s , r e p r e s e n t a t i v e s , d i s ~

• i

b u t

• r

s ,

and

joint venture

• partners. Such

d u e

diligence will

b e c

• n

d u c t e d

prior t

• the

r e t e n t i

• n
• f

a n y

n e w

a g e n t , consultant, r e p r e s e n t a t i v e , d i s t r i b u t

• r

,

• r

j

• i

n t v e n t u r e partner and.for

a l l

such

s a l e s i n t e r m e d i a r i e s w i l l

be u p d a t e d

n

• l

e s s

t h a n

• n

c e every

three years.

A t

a

m i n i m u m ,

s u c h d u e

d i l i g e n c e s h a l l include: a .

A

review

• f

the q u a l i f i c a t i

• n

s

a n d

b u s i n e s s reputation

• f

the

s a l e s i n t e r m e d i a r i e s ; b .

A

rationale for t h e

use

• f

t h e s a l e s intermediary;

and

A

review

• f

relevant

FCPA

risk areas.

12.

Where

d u e

diligence

• f

a

s a l e s

i n t e r m e d i a r y raises

a

serious red f l a g , t h e relevant information s h a l l

be

r e v i e w e d

by

p e r s

• n

n e l

f r

• m

the compliance

• r

legal divisions

w h

• h

a v e

received

F C P A

a n d

anti-corruption training.

1 3 .

Where

necessary

and

appropriate

a n d where p e r m i t t e d

by

a p p l i c a b l e law, P f i z e r has i n c l u d e d

a n d

w i l l include s t a n d a r d provisions

d e s i g n e d t

• prevent

v i a l a t i

• n

s

• f

the

FCPA

C . 2-7

SLIDE 11

a n d

• t

h e r applicable anti-corruption laws

a n d

r e g u l a t i

• n

s i n a g r e e m e n t s , c

• n

t a c t s , a n d renewals t h e r e

• f

w i t h . a g e n t s

a n d

b u s i n e s s p a r t n e r s , including: a . A n t i- c

• r

r u p t i

• n

representations

a n d undertakings

r e l a t i n g t

• c
• m

p l i a n c e w i t h the

anti-corruption

laws a n d

r e g u l a t i

• n

s ;

b. R i g h t s t

• conduct

a u d i t s

• f

the

b

• k

s a n d

r e c

• r

d s

• f

the a g e n t

• r

b u s i n e s s p a r t n e r that a r e r e l a t e d t

• t

h e i r

business w i t h Pfizer;

a n d

c . R i g h t s t

• t

e r m i n a t e the a g e n t

• r

b u s i n e s s p a r t n e r a s

a

r e s u l t

• f

any

b r e a c h

• f

a n t i

• c
• r

r u p t i

• n

l a w s a n d

regulations

• r

r e p r e s e n t a t i

• n

s

a n d

u n d e r t a k i n g s r e l a t e d to s u c h anti-corruption l a w s

a n d

r e g u l a t i

• n

s . T ` Y a i n i n ~

1 4 . P f i z e r has p r

• v

i d e d a n d

shall p r

• v

i d e : a . B i e n n i a l training

• n

a n t i- c

• r

r u p t i

• n

laws a n d

r e g u l a t i

• n

s t

• directors,
• fficers,

executives,

a n d e m p l

• y

e e s w

• r

k i n g i n

positions involving

a c t i v i t i e s

covered

b y

P f i z e r ' s p

• l

i c i e s r e g a r d i n g anti-corruption

a n d c

• m

p l i a n c e with t h e

FCPA;

b .

E n h a n c e d

F C P A

t r a i n i n g f

• r

a l l i n t e r n a l

a u d i t , f i n a n c i a l ,

c

• m

p l i a n c e and

l e g a l personnel involved in

FCPA

p r

• a

c t i v e reviews

• r

a n t i

• c
• r

r u p t i

• n

d u e

d i l i g e n c e r e l a t e d t

• the

p

• t

e n t i a l a c q u i s i t i

• n
• f

n e w

b u s i n e s s e s , i f n

• t

a l r e a d y q u a l i f i e d

a n d e x p e r i e n c e d ; a n d

c .

When

a p p r

• p

r i a t e

• n

the b a s i s

• f

a

F C P A

r i s k

assessment, p r

• v

i d e

FCPA

a n d

anti-corruption t r a i n i n g t

• relevant

a g e n t s

a n d

business

partners, at l e a s t

• n

c e e v e r y

three y e a r s . 15. Pfizer

has i m p l e m e n t e d a n d

shall m a i n t a i n

a s y s t e m

• f

a n n u a l

certifications

from

s e n i

• r

m a n a g e r s

in e a c h

• f

P f i z e r ' s B u s i n e s s Units, Divisions,

a n d

• p

e r a t i

• n

a l f u n c t i

• n

s (at t h e

market

• r

regional l e v e l ,

• r

the reasonable equivalent) as a p p r

• p

r i a t e , c

• n

f i r m i n g that

C . 2-8

SLIDE 12

their standard

• perating

procedures adequately iinplenlent P f i z e r ' s

a n t i

• corruption

policies, p r

• c

e d u r e s

and

controls, including t r a i n i n g requirements, that

t h e y have reviewed and f

• l

l

• w

e d

up

• n

any

issues identified in

F C P A

trend analyses,

a n d

that

t h e y a r e not a w a r e

• f

any

F C F A

• r
• ther

c

• n
• u

p t i

• n

i s s u e s t h a t

h a v e n

• t

already

b e e n

reported t

• t

h e Compliance Division

• r

the Legal Division.

C.2

• 9

SLIDE 13

A T ' ~ A C ' ~ I

l ~ T ' ~'e3 Pfizer Inc.

(

" P f i z e r

" )

agrees t

• p

e r i

• d

i c a l l y , at

no m

• r

e

t h a n

9-month

intervals

d u r i n g the term

• f

the D e f e r r e d P r

• s

e c u t i

• n

A g r e e m e n t b e t w e e n

the United S t a t e s Department

• f

J u s t i c e ,

C r i m i n a l D i v i s i

• n

, Fraud S e c t i

• n

( t h e "Department

" )

a n d

Pfizer

H . C . P . C

• r

p

• r

a t i

• n

dated

~~-

I~(the

"Pfizer

H C P D P A

" ) , r e p

• r

t t

• t

h e

Department t h e

s t a t u s

• f

P f i z e r ' s remediation

a n d i m p l e m e n t a t i

• n
• f

c

• m

p l i a n c e m e a s u r e s d e s c r i b e d i n A t t a c h m e n t s C . 1 a n d C . 2 . D u r i n g t h e t e r m

• f

t h e P f i z e r

H C P DPA,

should Pfizer d i s c

• v

e r c r e d i b l e e v i d e n c e , not already reported t

• the

Department,

t h a t q u e s t i

• n

a b l e

• r

corrupt

p a y m e n t s

• r

q u e s t i

• n

a b l e

• r

c

• r

r u p t transfers

• f

property

• r

i n t e r e s t s

m a y

h a v e b e e n

• f

f e r e d , p r

• m

i s e d ,

paid,

• r

a u t h

• r

i z e d

by a n y

Pfizer entity

• r

person,

• r

any

entity

• r

p e r s

• n

while w

• r

k i n g

d i r e c t l y for P f i z e r ,

• r

t h a t r e l a t e d f a l s e

books a n d

r e c

• r

d s

h a v e been m a i n t a i n e d ,

P f i z e r s h a l l report s u c h

c

• n

d u c t

t

• the

D e p a r t m e n t

i n t h e c

• u

r s e

• f

p e r i

• d

i c

c

• m

m u n i c a t i

• n

t

• b

e

scheduled b e t w e e n P f i z e r a n d t h e D e p a r t m e n t .

T h e

f i r s t

such update

s h a l l

take place

w i t h i n .

6

d a y s

a f t e r

t h e e n t r y

• f

t h e P f i z e r

H C P D P A .

D u r i n g

t h e term

• f

t h e Pfizer

H C P DPA,

P f i z e r s h a l l :

( 1 )

c

• n

d u c t a n

i n i t i a l

r e v i e w a n d s u b m i t a n

initial r e p

• r

t ,

and ( 2 ) conduct and p r e p a r e

t w

• f
• l

l

• w
• u

p r e v i e w s a n d

r e p

• r

t s , as d e s c r i b e d

b e l

• w

:

Pfizer s h a l l

submit

t

• t

h e

Department a

w r i t t e n report w i t h i n

1 8

calendar d a y s

• f

the entry

• f

the P f i z e r

H C P D P A

setting forth

a complete

d e s c r i p t i

• n
• f

i t s FCPA

a n d

a n t i

• c
• n

u p t i

• n

related remediation e f f

• r

t s

t

• d

a t e ,

i t s proposals

r e a s

• n

a b l y d e s i g n e d t

• improve

t h e p

• l

i c i e s

a n d procedures

• f

P f i z e r f

• r

ensuring c

• m

p l i a n c e w i t h

file FCPA

a n d

• t

h e r applicable a n t i

• corruption

l a w s , a n d t h e p a r a m e t e r s

• f

t h e s u b s e q u e n t r e v i e w s

C.3 -1

SLIDE 14

(the

" I ~ i i t i a l Report

"). The I n i t i a l

R e p

• r

t

shall

b e

transmitted t

• D

e p u t y C h i e f —

F C P A

U n i t , Fraud S e c t i

• n

, Criminal D i v i s i

• n

,

U . 5 . D e p a r t m e n t

• f

J u s t i c e ,

1 4

N e w

Y

• r

k A v e n u e , N.W.,

W a s h i n g t

• n

, D . C . 2 5 .

Pfizer

m a y

e x t e n d the t i m e p e r i

• d

for i s s u a n c e

• f

the

Initial

Report w i t h

p r i

• r

written approval

• f

t h e Department. 2. Pfizer shall u n d e r t a k e

two

f

• l

l

• w
• up

r e v i e w s

t

• t

h e

I n i t i a l

Report, i n c

• r

p

• r

a t i n g

a n y c

• m

m e n t s

p r

• v

i d e d

by

t h e Department

• n

t h e

Initial

Report, t

• f

u r t h e r

monitor and

assess

w h e t h e r

the p

• l

i c i e s

a n d procedures

• f

Pfizer a r e reasonably designed t

• detect

a n d p r e v e n t

v i

• l

a t i

• n

s

• f

the

FCPA

and

• ther

a p p l i c a b l e a n t i- c

• r

r u p t i

• n

laws.

T h e

first

f

• l

l

• w
• u

p r e v i e w and r e p

• r

t shall

b e completed by n

• later

than

2 7

d a y s

after

the

Initial

R e p

• r

t .

T h e

second f

• l

l

• w
• u

p r e v i e w a n d

r e p

• r

t shall

be

c

• m

p l e t e d

by n

• l

a t e r

than

2 7

days

a f t e r the

c

• m

p l e t i

• n
• f

the

first

f

• l

l

• w
• u

p r e v i e w and

r e p

• r

t ,

but not snore than

two

y e a r s

a n d s e v e n d a y s

after

t h e entry

• f

t h e P f i z e r

HCP

DPA.

P f i z e r

may

e x t e n d t h e t i m e p e r i

• d

for i s s u a n c e

• f

the f

• l

l

• w-up

reports with p r i

• r

written a p p r

• v

a l

• f

t h e D e p a r t m e n t . C . 3

• 2

SLIDE 15

I11~117[!7 ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ Pfizer Inc.

a g r e e s to

f u l f i l l

t h e conunitments

• u

t l i n e d i n

Attachment C.1, C . 2 a n d C . 3

• f

the Deferred ~'rosecution

A g r e e m e n t b e t w e e n

the United S t a t e s

D e p a r t m e n t

• f

Justice,

C r i m i n a l D i v i s i

• n

,

F r a u d

S e c t i

• n

and

Pfizer

H . C . P . C

• r

p

• r

a t i

• n

dated

~ , ~ ( ~

~~

AGREED

AND

CONSENTED

T O :

For

Pfizer I n c . i c e P r e s i d e n t

a n d General C

• u

n s e l

APPROVED:

,~.~

_

. . ~ " ~

~~

By:~

;

c

~ ,

B R E T

A .

C A M P B E L ? ~ , ~

PETER

B.

CLARK

Attorneys for Pfizer Inc. C . 4

• 1